Overview

A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH

Status:
Completed
Trial end date:
2019-10-22
Target enrollment:
Participant gender:
Summary
This is a Phase IIa, open-label, multiple dose, study in patients with PNH who have not received eculizumab (Soliris ®) in the past. A single cohort of subjects is planned for evaluation.
Phase:
Phase 2
Details
Lead Sponsor:
Apellis Pharmaceuticals, Inc.